LymphomaArchives
Indolent lymphoma care delivery and outcomes during the COVID‐19 pandemic in Ontario, CanadaLymphoma 5 min.
Indolent B‐cell non‐Hodgkin lymphomas comprise up to one third of all lymphomas and share similar disease courses and treatment paradigms. Bendamustine with the CD20 antibody rituximab (BR) has become the preferred initial treatment regimen for symptomatic patients based on improved progression‐free...
Tislelizumab augment the efficacy of CD19/22 dual‐targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B‐cell non‐Hodgkin lymphomaLymphoma 4 min.
Autologous CD19‐targeted chimeric antigen receptor T cells (CD19 CAR‐T) therapy has resulted in unprecedented response rate of >70% and improved 2‐year overall survival (OS) from 20% to 54% in refractory or relapsed B cell non‐Hodgkin lymphoma (R/R B‐NHL) patients. However,...
Current directions in the treatment of classical Hodgkin lymphomaLymphoma 2 min.
Optimal management of patients who present with advanced‐stage Hodgkin lymphoma remains a challenge. Most patients are cured with current treatment strategies, but approximately 20% of patients will experience disease progression. Additionally, both short and long‐term morbidity and mortality...
Disparities in care and outcomes for adolescent and young adult lymphoma patientsLymphoma 4 min.
Despite continued improvements in adolescent/young adult (AYA) lymphoma survival, outcome disparities persist. Even after consideration of factors thought to drive disparities (e.g., distance‐to‐care, treatment location) [1], non‐White (vs. White) patients are twice as likely to present...
Intravascular Large B-Cell LymphomaLymphoma 2 min.
Intravascular large B-cell lymphoma (IVBCL) is a very rare subtype of non-Hodgkin B-cell lymphoma. It was first reported by Pleger and Tappeiner in 1959 and characterized by restricted growth of neoplastic cells within the lumina of blood vessels [1]. Its incidence is estimated at 0.095/1 000 000 with...
